

**JAPAN VIETNAM MEDICAL INVESTMENT AND
DEVELOPMENT JOINT STOCK COMPANY**

**INTERIM CONSOLIDATED FINANCIAL
STATEMENTS**

Period from 01/07/2025 to 30/09/2025

CONTENTS

	Page
Balance Sheet	3 - 4
Income Statement	5 - 6
Cash Flow Statement	7 - 8
Notes to the Financial Statements	9 - 28

/// ★ M.S.D ///

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

From 01/07/2025 to 30/09/2025

REPORT OF THE BOARD OF GENERAL DIRECTORS

The Board of General Directors of JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY (the "Company") presents its report and the Company's interim Consolidated financial statements period from 01/07/2025 to 30/09/2025.

THE COMPANY

Japan Vietnam Medical Investment and Development Joint Stock Company ("the Company") formerly was established under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of Planning and Investment and registered for the 22st change on 14 July 2025.

BOARD OF MANAGEMENT, BOARD OF GENERAL DIRECTORSS AND BOARD OF SUPERVISION

The members of the Board of Management during the fiscal period and to the reporting date are:

Mr. Nguyen Hai Ha	Chairman	(To 21/04/2025)
Mr. Vu Khanh Din	Chairman	(Since 21/04/2025)
Mr. Pham Thanh Nam	Vice Chairman	
Mrs. Nguyen Thi Hanh	Member of BOD	
Mr. Nguyen Thi Phuong	Member of BOD	
Mr. Nguyen Van Chi	Member of BOD	

The member of the Board of Directors during the fiscal period and to the reporting date are:

- Mr. Vu Van Toan	CEO	(Since 24 April 2025)
- Mr. Pham Thanh Nam	CEO	(To 24 April 2025)
- Mr. Vu Van Toan	Deputy CEO	(To 24 April 2025)
- Mrs. Do Thi Ngoc Hoa	Deputy CEO	(To 1 April 2025)

The members of the Board of Supervision are:

Mr. Do Duc Hiep	Head	(Since 21 April 2025)
Mr. Nguyen Van Vy	Head	(To 21 April 2025)
Ms. Dang Thi Ha Giang	Member	
Ms. Nguyen Thi Tien Chi	Member	(To 21 April 2025)
Ms. Nguyen Vu Y Tan	Member	(Since 21 April 2025)

STATEMENT OF THE BOARD OF GENERAL DIRECTORS'S RESPONSIBILITY IN RESPECT OF THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The Board of General Directors is responsible for the interim Consolidated financial statements which give a true and fair view of the financial position of the Company, its operating results and its cash flows for the year. In preparing those interim Consolidated financial statements, the Board of General Directors is required to:

- Establish and maintain internal controls that the Company's Executive Board and Board of Directors determine are necessary to ensure the preparation and presentation of the interim consolidated financial statements are free from material misstatement, whether due to fraud or error;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim Consolidated financial statements;
- Prepare and present the interim Consolidated financial statements on the basis of compliance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of interim Separate financial statements;
- Prepare the interim Consolidated financial statements on going concern basis unless it is inappropriate to presume that the Company will continue in business.

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

From 01/07/2025 to 30/09/2025

The Board of General Directors is responsible for ensuring that accounting records are kept to reflect the financial position of the Company, with reasonable accuracy at any time and to ensure that the interim Consolidated financial statements comply with the registered accounting system. It is responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

We, The Board of General Directors, confirm that the interim Consolidated financial statements give a true and fair view of the financial position As at 30 September 2025, its operation results and cash flows in the period from 01/07/2025 to 30/09/2025 of the Company in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of interim Separate financial statements.

Other commitments

The Executive Board commits that the Company complies with Decree No. 155/2020/ND-CP dated 31 December 2020 on corporate governance applicable to public companies, Decree No. 245/2025/ND-CP as amended on 11 September 2025, and that the Company is not in breach of information disclosure obligations under Circular No. 96/2020/TT-BTC dated 16 November 2020 of the Ministry of Finance guiding information disclosure on the securities market.

On behalf of the Board of General Directors



Vu Van Toan
General Director

Hanoi, 30 Oct 2025

11A/KTB - 1011

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As of 30 Sep 2025

B01-DN/HN

Unit: VND

ASSETS	Codes	Notes	Ending balance	Opening balance
A - CURRENT ASSETS (100 = 110 + 120 + 130 + 140 + 150)	100		667,692,391,973	562,294,668,490
I. Cash and cash equivalents	110	V.1	20,736,435,912	19,581,608,627
1. Cash	111		19,316,435,912	19,431,608,627
2. Cash equivalents	112		1,420,000,000	150,000,000
II. Short-term investments	120		13,130,200,000	180,200,000
3. Investments held to maturity	123	V.2.1	13,130,200,000	180,200,000
III. Short-term receivables	130		497,968,312,159	387,304,882,539
1. Short-term trade receivables	131		243,393,434,131	444,972,468,085
2. Short-term advances to suppliers	132		128,682,111,735	309,447,807,995
3. Short-term loan receivables	135		4,576,315,789	4,700,000,000
4. Other short-term receivables	136	V.5	238,223,830,230	740,375,576,245
5. Allowance for doubtful debts	137		(116,907,379,726)	(1,112,190,969,786)
IV. Inventories	140	V.6	135,468,329,751	152,827,362,496
1. Inventories	141		156,394,003,323	172,126,118,935
2. Allowance for devaluation of inventories	149		(20,925,673,572)	(19,298,756,439)
V. Other current assets	150		389,114,151	2,400,614,828
1. Short-term prepaid expenses	151	V.7	214,697,290	1,666,605,150
2. Value added tax deductibles	152		174,416,861	729,067,910
3. Other receivables from State Budget	153		-	4,941,768
B - NON-CURRENT ASSETS (200 = 210 + 220 + 230 + 240 + 250 + 260)	200		338,218,887,526	265,808,003,685
I. Long-term receivables	210		1,517,108,920	1,517,108,920
6. Other long-term receivables	216	V.5	1,517,108,920	112,267,108,920
7. Allowance for long-term doubtful receivables	219		-	(110,750,000,000)
II. Fixed assets	220		90,410,141,383	101,266,116,561
1. Tangible fixed assets	221	V.8	89,320,417,130	99,947,101,736
Historical cost	222		573,094,725,827	572,990,184,114
Accumulated depreciation	223		(483,774,308,697)	(473,043,082,378)
3. Intangible fixed assets	227	V.10	1,089,724,253	1,319,014,825
Historical cost	228		5,313,999,620	5,313,999,620
Accumulated depreciation	229		(4,224,275,367)	(3,994,984,795)
IV. Long-term assets in progress	240		34,561,529,738	5,238,875,261
2. Construction in progress	242	V.12	34,561,529,738	5,238,875,261
V. Long-term financial investments	250		192,800,000,000	140,000,000,000
1. Investments in associates	252	V.2.5	750,000,000	750,000,000
2. Other long-term investments	253	V.2.3	192,800,000,000	140,000,000,000
3. Allowance for long-term investments	254		(750,000,000)	(750,000,000)
VI. Other long-term assets	260		18,930,107,485	17,785,902,943
1. Long-term prepaid expenses	261	V.7	16,809,580,971	16,524,418,246
2. Deferred tax assets	262		2,120,526,514	1,261,484,697
TOTAL ASSETS (270 = 100 + 200)	270		1,005,911,279,499	828,102,672,175

10/09/2025
 CÔNG TY CỔ PHẦN
 ĐẦU TƯ YẾN
 VANG

				Unit: VND	
RESOURCES	Codes	Notes	Ending balance	Opening balance	
C - LIABILITIES (300 = 310 + 330)	300		426,489,219,259	288,421,043,975	
I. Current Liabilities	310		393,510,280,571	288,286,032,550	
1. Short-term trade payables	311	V.14	50,700,420,210	87,795,950,428	
2. Short-term prepayments from customers	312	V.15.1	29,898,234,350	11,674,486,600	
3. Taxes and other payables to State Budget	313	V.16	11,661,559,816	25,439,864,101	
4. Payables to employees	314		2,340,701,092	6,896,320,667	
5. Short-term accrued expenses	315	V.17	7,640,477,198	9,130,658,468	
7. Other short-term payables	319	V.19	4,582,279,902	1,561,608,918	
8. Short-term loans and finance leases	320	V.20	278,146,628,024	140,828,584,046	
9. Provison for short-term payables	321		8,319,120,405	4,958,559,322	
II. Non-current liabilities	330		32,978,938,688	135,011,425	
4. Long-term loans and finance leases	338	V.20	32,977,822,238	-	
5. Deferred Tax Liabilities	341		1,116,450	135,011,425	
RESOURCES	Codes	Notes	Ending balance	Opening balance	
D - EQUITY (400 = 410)	400		579,422,060,240	539,681,628,200	
I. Owner's equity	410	V.21	579,422,060,240	539,681,628,200	
1. Owner's contributed capital	411		1,125,001,710,000	1,125,001,710,000	
- Ordinary shares with voting rights	411a		1,125,001,710,000	1,125,001,710,000	
2. Share premium	412		402,288,328,850	402,288,328,850	
5. Investment and development funds	418		19,211,235,252	19,211,235,252	
5. Retained earnings	421		(967,335,170,262)	(1,007,069,805,417)	
- Retained earnings until last period	421a		(1,007,069,805,417)	(1,047,352,036,211)	
- Retained earnings of this period	421b		39,734,635,155	40,282,230,794	
6. Non-controlling interest	429		255,956,400	250,159,515	
TOTAL RESOURCES (440 = 300 + 400)	440		1,005,911,279,499	828,102,672,175	

Preparer

Nguyen Thi Lua

Chief Accountant

Nguyen Ngoc Cuong

Hanoi, 30 October 2025

Chief Executive Officer



Vu Van Toan

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
From 01 Jul 2025 to 30 Sep 2025

B02-DN/HN

ITEMS	Codes	Notes	Quarter III 2025	Quarter III 2024	Unit: VND	
					Accumulated from the beginning to the end of this quarter (This year)	Accumulated from the beginning to the end of this quarter (Last year)
1. Revenue from goods sold and services rendered	01	VI.1	161,198,165,632	147,991,082,675	478,451,991,050	423,875,959,782
2. Revenue deduction	02	VI.2	-	35,595,238	151,076,190	40,695,238
3. Net Revenue from goods sold and services rendered	10		161,198,165,632	147,955,487,437	478,300,914,860	423,835,264,544
4. Cost of goods sold	11	VI.3	123,412,424,368	115,249,764,056	364,370,298,447	324,968,046,482
5. Gross profit from goods sold and services rendered (20=10-11)	20		37,785,741,264	32,705,723,381	113,930,616,413	98,867,218,062
6. Financial income	21	VI.4	588,255,352	3,655,717,647	4,960,342,638	13,895,008,223
7. Financial expenses	22	VI.5	4,993,620,423	1,962,517,332	11,740,138,745	4,648,578,599
<i>Of which: interest expense</i>	23		4,988,065,423	1,218,673,987	9,669,186,515	3,856,184,080
8. Selling expenses	25	VI.6	12,271,616,405	13,790,348,504	37,320,481,208	47,874,167,604
9. General and Administration expenses	26	VI.7	8,150,792,945	13,050,666,300	29,515,063,455	35,240,862,044
10. Operating profit (30=20+(21-22)+24-(25+26))	30		12,957,966,843	7,557,908,892	40,315,275,643	24,998,618,038
11. Other income	31	VI.8	2,737,801,935	2,982,846,827	10,173,229,855	7,957,062,590
12. Other expenses	32		58,625	244,917,236	699,052,457	3,497,470,034
13. Profit from other activities (40=31-32)	40		2,737,743,310	2,737,929,591	9,474,177,398	4,459,592,556
14. Accounting profit before tax (50=30+40)	50		15,695,710,153	10,295,838,483	49,789,453,041	29,458,210,594
15. Current corporate income tax	51	VI.9	2,898,916,538	2,150,939,282	10,925,652,270	6,736,966,081
16. Deferred corporate income tax expense	52		173,539,288	(300,653,337)	(876,631,270)	(1,204,304,485)

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
From 01 Jul 2025 to 30 Sep 2025

B02-DN/HN

ITEMS	Codes	Notes	Unit: VND			
			Quarter III 2025	Quarter III 2024	Accumulated from the beginning to the end of this	Accumulated from the beginning to the end of this
18. Profit after tax (60=50-51-52)	60		12,623,254,327	8,445,552,538	39,740,432,041	23,925,548,998
19. Profit after tax of Parent Company	61		12,288,804,483	8,435,131,503	39,734,635,155	23,905,542,167
20. Profit after tax of Non-Controlling Interest	62		5,149,570	10,421,035	5,796,886	20,006,831
21. EPS	70		112	75	353	213

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Ngoc Cuong

Hanoi, 30 October 2025
Chief Executive Officer



Vu Van Toan

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
From 01 Jan 2025 to 30 Sep 2025
(Indirect Method)

B03-DN/HN

ITEMS	Codes	Notes	This period	Last period
I. Cash flows from operating activities				
<i>Profit before tax</i>	<i>01</i>		<i>49,789,453,041</i>	<i>29,458,210,594</i>
<i>Adjustment for</i>				
Depreciation and amortization and goodwill	02		18,440,292,922	35,890,555,508
Allowance and provisions	03		8,289,211,234	3,611,333,368
Foreign exchange gain (loss) upon revaluation of monetary items denominated in foreign currency	04		260,293,890	4,357,000
Gain/Loss from investing activities	05		(6,469,517,964)	(3,768,857,723)
Interest expenses	06		9,669,186,515	3,856,184,080
<i>Operating profit before working capital movements</i>	<i>08</i>		<i>79,978,919,638</i>	<i>69,051,782,827</i>
Increase, decrease in receivables	09		(142,095,678,518)	62,644,028,672
Increase, decrease in inventories	10		15,732,115,612	(64,151,292,435)
Increase, decrease in payables (exclude interest expense, CIT)	11		(30,936,290,878)	22,862,467,137
Increase, decrease prepayments	12		1,166,745,135	(3,017,794,025)
Interest paid	14		(9,457,077,729)	(3,897,828,510)
Coporate income tax paid	15		(15,655,827,218)	(4,765,118,746)
<i>Net cash from operating activities</i>	<i>20</i>		<i>(101,267,093,958)</i>	<i>78,726,244,920</i>
II. Cash flows from investing activities				
Acquisition of fixed assets and other long-term assets	21		(37,939,606,516)	(11,812,484,622)
Proceeds from disposals of fixed assets and	22		3,760,575,000	6,005,397,073
Cash outflow for lending, acquiring debt instruments of other entities	23		(498,350,000,000)	(467,200,000,000)
Cash recovered from lending, selling debt instruments of other entities	24		505,522,368,422	240,210,000,000
Cash outflow for investments in other entities	25		(99,726,000,000)	-
Cash recovered from investments in other entities	26		46,926,000,000	-
Interest earned, dividend an profit received	27		11,932,718,121	1,427,605,120
<i>Net cash from investing activities</i>	<i>30</i>		<i>(67,873,944,973)</i>	<i>(231,369,482,429)</i>
III. Cash flows from financial activities				
Proceeds from borrowings	33		500,259,496,909	156,516,362,938
Repayment for borrowings	34		(329,963,630,693)	(148,118,277,977)
<i>Net cash from financial activities</i>	<i>40</i>		<i>170,295,866,216</i>	<i>8,398,084,961</i>

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (continued)
From 01 Jan 2025 to 30 Sep 2025
(Indirect Method)

B03-DN/HN

ITEMS	Codes	Notes	This period	Last period
Net cash during the period	50		1,154,827,285	(144,245,152,548)
Cash and cash equivalents at the beginning	60	5	19,581,608,627	152,936,802,760
Cash and cash equivalents at the ending	70	5	20,736,435,912	8,691,650,212

Preparer



Nguyen Thi Lua

Chief Accountant



Nguyen Ngoc Cuong

Lập ngày 30 tháng 10 năm 2025

Chief Executive Officer



Vu Van Toan

11/10/2025

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

I. GENERAL INFORMATION

1.1 Structure of ownership

Japan Vietnam Medical Investment and Development Joint Stock Company (“the Company”) formerly was Japan Medical Equipment Joint Stock Company, operated under the Certificate of Business Registration No. 0101178800 dated 27 September 2010 issued by the Hanoi Department of

The Company’s head office is located at Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City, Viet Nam

The Company’s chartered capital is VND 1,125,001,710,000 equivalent to 112,500,171 shares, per value per share is VND 10,000. The Company's shares are listed on the Ho Chi Minh City Stock Exchange (HOSE) with the stock code JVC.

Total employees of the group as at 30 Sep 2025 was 167 (at 01 Jan 2025 was 164)

1.2. Operating industry and principal activities

The Company’s principal activities include:

- Wholesale of medical equipment and instruments;
- Lease of medical equipment and instruments;
- Associate investment medical equipments;
- General clinic, specialits clinic and dental clinic;
- Financial investment activities

1.3. Normal production and business cycle

The Company’s normal course of business cycle is no more than 12 months

1.4. Corporate structure

The Company have a branch located at No. 218 Tran Hung Dao Street, 11 Ward, Ho Chi Minh City which operating in wholesales of medical machinery and equipments.

As at 30 Sep 2025, the Company have 02 subsidiaries and 01 associate company as follow:

Subsidiaries	Principal activites	Address	Ownership ratio	Voting right ratio
- Kyoto Medical Science Company Limited.,	No business operations in the first 6 months of the year	Floor 24, Icon4 Building, No. 243A De La Thanh Street, Lang Ward, Hanoi City.	100.00%	100.00%
- Vietnam Japan Medical Technology Investment Joint Stock Company	General clinic, specialits clinic and dental clinic	Floor 1, No. 163 Hoang Cau Street, Dong Da Ward, Ha Noi City.	99.00%	99%
Subsidiaries	Principal activites	Address	Ownership ratio	Voting right ratio
- VIET TIN MEDICAL EQUIPMENT JSC	Traing medical equipments	No. 19 Vo Van Tan Street, 6 Ward, Ho Chi Minh City	25.00%	25%

II. ACCOUNTING PERIOD AND ACCOUNTING CURRENCY

2.1 The Company’s fiscal year begins on 01 Jan and ends on 31 Dec of the year

2.2 The currency unit used in accounting
The currency unit used in accounting period is Vietnam Dong (VND)

3 ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM APPLIED

The consolidated financial statements are expressed in Vietnamese Dong (VND) and prepared under the accounting principles in conformity with Circular No. 202/2014/TT-BTC dated 22 December 2014 of Ministry of Finance, the Vietnamese corporate accounting system issued in pursuance of Circular No. 200/2014/TT-BTC dated 22 December 2014, Circular No. 53/2016/TT-BTC dated 21 March 2016 of Ministry of Finance, Vietnamese Accounting Standards, and the relevant statutory requirements applicable to consolidated financial reporting

4 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies, which have been adopted by the Company in the preparation of these financial statements, are as follows:

4.1. Basis of consolidation

The consolidated financial statements are prepared on the accrual basis (except for the information related to cash flows) under historical cost principle, based on the assumption of going concern.

The consolidated financial statements include the financial statements of the Company and enterprises controlled by the Company (its subsidiaries) up to 30 Sep 2025. Control is achieved where the Company has the power to govern the financial and operating policies of an investee enterprise so as to obtain benefits from its activities.

The results of subsidiaries acquired or disposed of during the year are included in the consolidated income statement from the effective date of acquisition or up to the effective date of disposal, as appropriate.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used in line with those used by the Company.

Intragroup transactions and balances are eliminated in full on consolidation.

Non-controlling interests (NCIs) are presented in the consolidated balance sheet within equity, separately from the equity of the owners of the parent. NCIs in net assets of subsidiaries include: NCIs are recorded at the fair value of identifiable assets and liabilities at the acquisition date, NCIs in changes of equity from acquisition date up to the beginning of the current period and NCIs in changes of equity during current period. NCIs in the consolidated income statement is also separately presented.

4.2. Estimates

The preparation of consolidated financial statements in conformity with Vietnamese accounting standards, the Vietnamese corporate accounting system, and the relevant statutory requirements applicable to consolidated financial reporting requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. The actual number incurred may differ from the estimates and assumptions.

4.3. Cash and cash equivalent

Cash reflects the full existing amount of the Company at the end of the accounting period, comprising cash on hand, demand deposits and cash in transit.

Cash equivalents include short-term investments with maturity less than 03 months since the date of investment, which can be converted easily into a certain amount of cash without any risk in conversion into cash at the reporting date and recorded following Vietnamese Accounting Standard No. 24 - Cash flow statement.

4.4. Conversion of foreign currencies

During the period, transactions arising in foreign currencies are converted into VND at exchange rates ruling at the transaction dates or accounting book exchange rate. Foreign exchange differences arising from these transactions are recognized in financial income (if gain) and financial expense (if loss). Monetary items denominated in foreign currencies are translated using exchange rate ruling at the balance sheet date. Foreign exchange differences arising from revaluation are reflected in the foreign exchange rate differences account and the balance of this account is transferred to the financial income (if profit) or financial expense (if loss) at the end of the accounting period.

4.5. Held to maturity investment

Reflecting the investments that the Company has intention and ability to hold to maturity with remaining maturity not exceeding 12 months (short-term) and more than 12 months (long-term) from the reporting date (except trading securities), including time deposits (including treasury bills, promissory notes), bonds, commercial papers, preference stocks which the issuer is obliged to buy at a certain time in the future, held-to-maturity loans for the purpose of collecting periodic interest, other kinds of debt securities (e.g. investment in buying bad debts, etc.) and other held-to-maturity investments, not including those already presented in the items such as "cash equivalents", "receivables from short-term borrowings" and "receivables from long-term borrowings".

Held-to-maturity investments are initially recognized at cost, including purchase price and expenses related to the purchase of investments such as brokerage fees, transaction, advisory, tax fees and bank charges ... After initial recognition, these investments are recorded at recoverable value.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

Interest incurred after the date of purchase of held-to-maturity investments, profit upon disposals or sale of held-to-maturity investments are recorded in financial income. Interest received before the investment date is deducted from the cost at the date of purchase.

The Company bases on the remaining term from the reporting date to classify held-to-maturity investments as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies under the principle presented in note No. 4.4.

When having strong evidence indicating part or all of the investments may not be recoverable and the losses can be measured reliably, these losses are recorded in financial expenses in the year and reduced directly to the value of the investments. Provision for held-to-maturity investments is similar to receivables unlikely to recover, is made similarly to bad debts according to note No. 4.7.

4.6 Receivables and provision for doubtful debts

Receivables are monitored detailed under the original terms, remaining terms at the reporting date, the receivable objects, receivable foreign currencies and other factors for the Company's management purpose. The classification of receivables comprised of trade receivables, and other receivables shall comply with the principles:

- Trade receivables include commercial receivables incurred from purchase-sale transactions, including receivables from sale of exported goods under the trust for other entities;
- Other receivables include non-commercial or non-trading receivables, including: receivables from loan interests, deposit interests, amount paid on behalf of another party; receivables which the export trustor must collect from the trustee; receivables from penalties, compensation; advances; pledges, collaterals, deposits, assets lending...

The company bases on the remaining term at the reporting date receivables to classify as long-term or short-term and the revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

Receivables are recognised not exceeding the recoverable value. Provision for doubtful debts is made for receivables that are overdue for six months or more, or when the debtor is in difficulty of solvency due to dissolution, bankruptcy, or similar difficulties in accordance with the prevailing corporate accounting system.

4.7 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost comprises purchase price, processing cost and other direct attributable expenses that have been incurred in bringing the inventories to their present location and condition. Net realisable value represents the estimated selling price less all estimated costs to completion and costs to be incurred in marketing, selling and distribution. Cost is calculated using the weighted average method. Inventories are recorded by perpetual method.

The provision for the devaluation of inventories is the excess of the inventories' cost over their net realizable value at the accounting year end and made in accordance with prevailing corporate accounting system.

4.8 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Tangible fixed assets are recognized under the historical cost.

The costs of tangible fixed assets arising from purchases and self-constructions comprise all costs of bringing the tangible fixed assets to their working condition for their intended use.

The cost of self-construction or manufactured assets are the actual construction or manufacturing cost plus installation and test running costs.

Costs incurred after initial recognition are recorded as increase in the historical cost of assets if they actually improve the current status in comparison with the initial standard status of the assets, such as:

- Parts of the tangible fixed asset are modified to extend their useful life or to increase their capacity; or
- Parts of the tangible fixed asset are upgraded to substantially increase product quality; or
- New technology process is applied to reduce operation expenses of the assets in comparison with before.

The costs incurred for repairs and maintenance aims to restore or maintain the ability to bring the economic benefits of the assets according to the initial standard status, do not meet one of the above conditions, are recognized in the operation costs during the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives in accordance with Circular No. 45/2013/TT-BTC dated 25/04/2013 of the Ministry of Finance. The estimated useful lives are as follows:

Years

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

Buildings and structures	5
Machinery and equipment	03-12
Motor vehicles	06-10
Office equipment	03-06

Loss or gain resulting from sales and disposals of tangible fixed assets is the difference between proceed from sales or disposals of assets and their residual valuwes and is recognized in the income statement.

4.9 Intangible assets and amortisation

Intangible assets comprise software and are stated at cost less accumulated amortization. Software is measured initially at purchase cost and is amortized on a straight-line basis over an estimated useful life from 03 years to 06 years.

4.10 Construction in progress

The construction in progress is recorded at cost, including expenses directly related to (including borrowing costs by the Company’s accounting policy) properties in the course of construction for production, equipment installed for the purpose of manufacturing, rental and management as well as related expenses to repairs of fixed assets. Depreciation of these assets, on the same basis as other assets, commences when the assets are ready for their intended use.

4.11 Prepaid expenses

Prepaid expenses are expenses which have already been paid but relate to results of operations of multiple accounting periods. The Company’s prepaid expenses include the value of tools and supplies, cost of repairing Machinery and Equipments and others.

Payables

The payables are monitored detailed under the original terms, the remaining terms at the reporting date, the payable objects, type of payables denominated in foreign currency and other factors according to the Company’s management purpose. The classification of payables such as trade payables, other payables must be implemented the following principles:

- Trade payables include commercial payables incurred from purchase-sale transactions, including payables when imported goods under the trust;
- Other payables include non-commercial or non-trading payables, including: payables for loan interest, dividend and earning payables; payables for financial investments; amount paid for the third party; amount which the truster receives from relevant parties to pay under the entrusted import-export transactions; asset borrowings; payables for penalties, compensation; surplus assets without reason; payables for social insurance, medical insurance, unemployment insurance, trade union; collaterals, deposits received, etc.

The company bases on the remaining terms of payables at the reporting date to classify as long-term or short-term and perform revaluation of monetary items denominated in foreign currencies according to the principles as presented in the note No. 4.4.

The payables are recorded not less than the payment obligations. In the case of there is evidence that a loss likely occurs, the Company recognizes immediately a payable under the prudent principle.

4.12 Payables Provisions

Provision for liabilities is recognized only if the following conditions are fulfilled: The Company is responsible for current liabilities (legal liability or joint liability) due to consequences of any happened event; Possible decrease in economic benefits requires the settlement of liabilities; and Provide a reliable estimation of liabilities’ value.

Provision for liabilities is recorded at the best estimate of the amount paid for current liabilities as at the end of the accounting period.

4.13 Loans and finance lease liabilities

The loans and finance lease liabilities are monitored detailed for each loan object, loan agreement, and loan asset; for the term of loan and finance lease liabilities and type of foreign currency (if any). The loans and finance lease liabilities with the remaining term more than 12 months from the reporting date are presented as long-term loans and finance lease liabilities. The due loans and finance lease liabilities within the next 12 months from the reporting date are presented as short-term loans and finance lease liabilities.

4.14 Borrowing costs

Borrowing costs include interests and other costs incurred directly related to the loans.

Borrowing cost is charged to operating expenses during the period when incurred, except for borrowing costs directly attributable to the construction or production of qualifying assets with appropriate time (more than 12 months) to put into use for the intended purposes or sales, which recorded in the value of capitalized assets whether it is subject to the fulfillment of certain conditions of Vietnamese Accounting Standard No. 16 - Borrowing cost. Borrowing costs directly attributable to the construction of fixed assets, investment properties can be capitalized even though the construction is less than 12 months.

Revenue from the sale of goods shall be recognized if it simultaneously meets the following conditions:

- a) The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer
- b) The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- c) revenue has been determined with relative certainty. When contracts define that buyers are entitled to return products, goods purchased under specific conditions, the Company shall only record turnovers if such specific conditions no longer exist and buyers are not entitled to return products, goods (unless the customer is entitled to return the goods under the form of exchange for other goods or services);
- d) The Company has gained or will gain economic benefits from the good sale transaction; and
- e) It is possible to determine the costs related to the goods sale transaction.

Revenue recognition from services rendered if simultaneously satisfying the following conditions:

- a) Revenue is measured reliably. When the contracts define that the customers are entitled to return service purchased under specific conditions, the Company shall only record revenue if such specific conditions do not exist and the customers are not entitled to return services provided;
- b) The Company received or will receive economic benefits from the sale transactions;
- c) The completed work is determined at the reporting date; and
- d) Incurred costs for the transaction and the costs to complete the transaction of providing such services is determined.

Revenue from financial activities includes: comprises deposit interest, profit from bond investment, profit from financial investment cooperation contract, discounted payments, gains from foreign exchange differences and others (if any).

Other income reflects income arising from the events or separate transactions with normal business operations of the Company, besides the above revenue.

Corporate income tax represents the sum of the current tax and deferred tax.

The current tax expense represents corporate tax payables incurred for the current year and additional corporate tax payables due to immaterial errors in last year. The current tax income represents corporate tax payables deducted due to immaterial errors in last year.

Deferred tax expenses reflect the excess of reverted deferred tax assets and arisen deferred tax assets or the excess of arisen deferred tax payables and reverted deferred tax payables during the year. Deferred tax income reflects the excess of arisen deferred tax assets and reverted deferred tax assets or the excess of reverted deferred tax payables and arisen deferred tax payables during the year.

Deferred tax is recognized on significant differences between carrying amounts and the corresponding tax bases of assets and liabilities in the financial statements, tax losses, and unused tax incentives. Deferred tax liabilities are generally recognized for all temporary differences and deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Corporation intends to settle its current tax assets and liabilities on a net basis.

Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years (including loss carried forward, if any) and it further excludes items that are never taxable or deductible.

The determination of the taxes borne by the Corporation is based on the current interpretation of tax regulations. However, these regulations are subject to periodic variation and their ultimate determination depends on the results of the tax authorities' examinations.

Other taxes are applied in accordance with the prevailing tax laws in Vietnam.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

4.17 Related parties

The parties are regarded as related parties of the Company if they have the ability to control or exercise significant influence over the Company in making financial and operating decisions or have the same key management personnel or jointly managed by another Company.

Individuals with the direct or indirect voting rights can impact significantly to the Company, including close family members of these individuals (parents, spouses, children, siblings).

Key management personnel have authority and responsibility for planning, managing and controlling the operation of the Company: the directors, the managers of the Company and close family members of these individuals.

The companies managed by these individuals mentioned above with direct or indirect voting rights or through these rights they can have a significant impact on the Company, including the companies owned by the leaders or major shareholders of the Company and the companies have the same key management personnel.

5 Cash and cash equivalents

	30-Sep-25	01-Jan-25
Cash on hand	1,650,791,955	
Cash in bank	17,665,643,957	19,431,608,627
Total	19,316,435,912	19,431,608,627
Cash equivalents	1,420,000,000	150,000,000
Total Cash and cash equivalents	20,736,435,912	19,581,608,627

6 Financial investment

6.1 Short-term investments held to maturity

	30-Sep-25	01-Jan-25
Term - Deposit	13,130,200,000	180,200,000
Total	13,130,200,000	180,200,000

6.2 Other short-term investments

	30-Sep-25		01-Jan-25	
	Value	Provision	Value	Provision
Investments in other entities	192,800,000,000		140,000,000,000	
TNG Investment and Construction Company Limited	140,000,000,000		140,000,000,000	
Others	52,800,000,000			
Total	192,800,000,000		140,000,000,000	

6.3 Investments in associates

	30-Sep-25		01-Jan-25	
	Value	Provision	Value	Provision
Investments in joint ventures	750,000,000	(750,000,000)	750,000,000	(750,000,000)
- Viet Tin Medical Devices JSC	750,000,000	(750,000,000)	750,000,000	(750,000,000)

7 Short-term trade receivables

	30-Sep-25	01-Jan-25
A1 Investment JSC	9,061,795,788	97,904,625,613
Huong Dong Comercial JSC	48,693,747,216	95,620,562,655
Triet Ton Tien Medical Devices JSC	10,492,501,970	28,031,022,362
16A Ha Dong Ltd Company	9,920,595,600	26,012,725,600

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

HOAN MY TECHNOLOGY DEVELOPMENT INVESTMENT COMPANY LIMITED	26,738,404,395	-
Cho Ray Hospital	8,579,312,000	-
Nghe An General Friendship Hospital	9,542,060,000	1,810,500,000
Bach Mai Hospital	12,317,369,780	3,368,400,000
Other Customers	108,047,647,382	192,224,631,855
Total	243,393,434,131	444,972,468,085

8 Short-term advances to suppliers

	30-Sep-25	01-Jan-25
JWB Co.	-	190,230,906,514
Nishimura Medical Instrument Co.,Ltd	-	29,872,783,121
Medical Devices Ltd Company	-	24,725,000,000
RC Pharmaceutical and Medical Equipment Production & Trading Co., Ltd.	-	21,080,000,000
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	12,240,360,000
HAI PHAT MEDICAL EQUIPMENT COMPANY LIMITED	93,395,000,000	2,380,843,957
Other Customers	23,046,751,735	28,917,914,403
Total	128,682,111,735	309,447,807,995

9 Other receivables

	30-Sep-25	01-Jan-25
Short-term		
Receivables from interests	263,361,432	7,676,099,434
Advances	12,394,934,229	78,314,763,458
Deposit	355,109,352	427,328,242
Prepayments, guarantee and payment on behalf (1)	-	403,295,265,000
Shortage of assets awaiting resolution	3,778,695,966	7,242,748,952
Receivable of BCC (3)	216,025,000,000	236,200,000,000
Others	5,406,729,251	7,219,371,159
Total	238,223,830,230	740,375,576,245
Long-term		
Mortgages	1,517,108,920	1,517,108,920
Triet Ton Tien Medical Devices JSC (2)	-	110,750,000,000
Total	1,517,108,920	112,267,108,920

(1) Amounts that Compay prepaid, guarant, and paid on behalf relating to key managerial predecessors before 2015

(2) Capital contribution according to the Capital Contribution Contract for the medical associate project No 01/TTT-JVC/HĐGV on 22 September 2014 between JVC and Triet Ton Tien JSC to carry out the medical device associate project at the Hospital. Company defines that it can not gain benefit from this contract and made a provision of 100% for damages from 31 Mar 2016.

(3) Are financial investing cooperation amount with partners with a view to make profit, the cooperative periods are from 6 to 12 months

On March 26, 2025, the Company issued Resolution No. 2603/2025/NQ-HĐQT-JVC regarding to the write-off of fully provisioned bad debts, which have been transferred off-balance sheet for monitoring purposes. Total: 584.571.745.440 VND

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

10 DOUBTFUL DEBTS

Receivables that are overdue or not yet due but are doubtful of collection

	30-Sep-25			01-Jan-25		
	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>	<i>Historical cost</i>	<i>Allowance</i>	<i>Recoverable Amount</i>
<i>Short-term receivables</i>						
A1 Investment JSC	9,061,795,788	(9,061,795,788)	-	97,904,625,613	(97,904,625,613)	-
Huong Dong Comercial JSC	48,693,747,216	(48,693,747,216)	-	95,620,562,655	(95,620,562,655)	-
Triet Ton Tien Medical Devices JSC	10,492,501,970	(10,492,501,970)	-	28,031,022,362	(28,031,022,362)	-
16A Ha Dong Ltd Company	9,920,595,600	(9,920,595,600)	-	25,496,725,600	(25,496,725,600)	-
Medical Devices and Project Ltd Company	-	-	-	10,797,500,000	(10,797,500,000)	-
Huu nghi Viet Duc Hospital	3,231,100,000	(1,615,550,000)	1,615,550,000	-	-	-
Song Viet Ltd. Company	1,896,450,000	(1,896,450,000)	-	-	-	-
Other Customers	4,552,318,121	(2,998,691,853)	1,553,626,268	75,297,727,049	(67,878,581,609)	7,419,145,440
<i>Advance payments to suppliers</i>						
JWB Co.	-	-	-	190,230,906,514	(190,230,906,514)	-
Nishimura Medical Instrument Co.,Ltd	-	-	-	29,872,783,121	(29,872,783,121)	-
Medical Devices Ltd Company	-	-	-	24,725,000,000	(24,725,000,000)	-
RC Pharmaceutical and Medical Equipment Production & Trading Co., Ltd.	-	-	-	21,080,000,000	(21,080,000,000)	-
Gold Lite Pte. Ltd	-	-	-	14,851,200,000	(14,851,200,000)	-
An Thanh Phat Medical Devices Ltd, Company	12,240,360,000	(12,240,360,000)	-	-	-	-
Toan Dan Law Firm Co., Ltd.	2,022,597,471	(2,022,597,471)	-	-	-	-
Other Customers	30,013,973	(30,013,973)	-	18,484,176,504	(13,945,241,017)	4,538,935,487

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

	30-Sep-25			01-Jan-25		
	Historical cost	Allowance	Recoverable Amount	Historical cost	Allowance	Recoverable Amount
Total value of overdue other receivables						
Triet Ton Tien Medical Devices JSC (Short-term + Long-term)	-	-	-	426,110,806,472	(426,110,806,472)	-
Huong Dong Comercial JSC	-	-	-	87,934,458,528	(87,934,458,528)	-
Other Customers	17,935,075,855	(17,935,075,855)	-	88,461,556,295	(88,461,556,295)	-
Total	120,076,601,924	(116,907,379,726)	3,169,176,268	1,234,899,050,713	(1,222,940,969,786)	11,958,080,927

11 Inventories

	30-Sep-25		01-Jan-25	
	Historical cost	Allowance	Historical cost	Allowance
Goods in transit	6,677,772,638	-	8,971,969,181	-
Work in progress	166,929,663	-	1,042,368,808	-
Goods for sales	126,754,619,072	(20,297,829,894)	158,183,362,880	(19,062,849,741)
Goods on consignment	22,794,681,950	-	3,928,418,066	(235,906,698)
Total	156,394,003,323	(20,297,829,894)	172,126,118,935	(19,298,756,439)

12 Prepaid expenses

	30-Sep-25	01-Jan-25
Short-term		
Dispatched tools and supplies	160,475,957	1,291,953,114
Others	54,221,333	374,652,036
Total	214,697,290	1,666,605,150
Long-term		
Dispatched tools and supplies	9,506,716,604	8,181,282,512
Spare parts and replacement components	3,135,126,972	2,607,372,023
Warehouse and structural repair expenses	4,298,998,246	5,464,056,239
Others		271,707,472
Total	16,940,841,822	16,524,418,246

13 Tangible fixed assets

Appendix No. 01

14 Intangible fixed assets

Appendix No. 02

15 Assets in progress

	30-Sep-25	01-Jan-25
Construction in progress	34,561,529,738	5,238,875,261
Total	34,561,529,738	5,238,875,261

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

16 Short-term trade payables

	30-Sep-25		01-Jan-25	
	<i>Outstanding balance</i>	<i>Repayment capability amount</i>	<i>Outstanding balance</i>	<i>Repayment capability amount</i>
FujiFilm Vietnam Co.,Ltd	29,984,722,450	29,984,722,450	48,960,720,612	48,960,720,612
Danh Medical Instruments Ltd.			17,925,060,598	17,925,060,598
Konica Minolta, Inc	5,003,441,572	5,003,441,572	16,978,185,518	16,978,185,518
UNITED IMAGING HEALTHCARE HONG	11,941,890,000	11,941,890,000		
Others	3,770,366,188	3,770,366,188	3,931,983,700	3,931,983,700
Total	50,700,420,210	50,700,420,210	87,795,950,428	87,795,950,428

17 Prepayments from customers

	30-Sep-25	01-Jan-25
SAI GON NAM DINH GENERAL CLINIC JSC		4,892,500,000
National Hospital of Pediatrics		1,797,075,000
Tam Viet Technical Service Commercial Investing Co.,LTD		1,330,000,000
108 Military Central Hospital		1,673,264,340
Hop Luc General Hospital One Member Limited Liability Company	23,300,690,000	
Others	6,597,544,350	1,981,647,260
Total	29,898,234,350	11,674,486,600

18 Taxes and other payables to State Budget
Appendix No. 03

19 Loans and finance leases
Appendix No. 04

20 Short-term Accrued Expenses

	30-Sep-25	01-Jan-25
Profesional consulting expense	5,303,255,718	5,538,465,918
Payables for BCC individuals		1,995,208,042
Business Commission expense	2,119,155,779	1,341,788,856
Interest Expense	218,065,701	133,271,983
Others		121,923,669
Total	7,640,477,198	9,130,658,468

21 Other payables

Short-term other payables

	30-Sep-25	01-Jan-25
Trade union fee,SHUI	249,485,836	306,300
Payables of received BCC capital(1)	-	867,104,158
Deposits and collaterals received	59,500,000	59,500,000
Others	4,273,294,066	1,020,216,912
Total	4,582,279,902	1,947,127,370

(1) Payables related to capital contributions received from individuals under business cooperation contracts for the purchase of assets located at hospitals.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

22 Equity

	30-Sep-25		01-Jan-25	
	VND	%	VND	%
Contributed capital	1,125,001,710,000	100%	1,125,001,710,000	100%
Total	1,125,001,710,000	100%	1,125,001,710,000	100%

Capital transactions with owners and dividend distribution, profit sharing:

	30-Sep-25	01-Jan-25
Paid-in equity		
+ Opening balance	1,125,001,710,000	1,125,001,710,000
+ Ending balance	1,125,001,710,000	1,125,001,710,000
Devidend, profit distributed	-	-

	30-Sep-25	01-Jan-25
	VND	VND
Number of outstanding shares	112,500,171	112,500,171
Common shares	112,500,171	112,500,171
Par Value of outstanding shares	10.000 VND	10.000 VND

23 Revenue from goods sold and services rendered

	This period	Last period
Revenue from goods sold	138,255,553,515	119,110,349,281
Revenue from services rendered	5,579,923,680	15,214,865,622
Other revenue	17,362,688,437	13,665,867,772
Total	161,198,165,632	147,991,082,675

24 Revenue deduction

	This period	Last period
Revenue deduction		35,955,238
Total	-	35,955,238

	This period	Last period
Revenue from related parties		
- Tasco Joint Stock Company	23,083,200	367,893,090

25 Cost of goods sold and services rendered

	This period	Last period
Cost of goods sold	113,029,236,854	94,278,732,707
Cost of services rendered	553,916,251	8,608,210,552
Cost of leasing investment properties	9,201,427,585	11,260,528,582
Allowance for devalutaion of inventories	627,843,678	1,102,292,215
Total	123,412,424,368	115,249,764,056

26 Financial Income

	This period	Last period
Bank and loan interest	245,975,620	1,746,964,617
Profit from financial investment cooperation contract		1,860,498,630
Profit from bond investment	312,160,231	48,254,400
Gain con foreign exchange difference	30,119,501	
Total	588,255,352	3,655,717,647

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

27 Financial Expenses

	This period	Last period
Interest expense	4,988,065,423	1,218,673,987
Loss on foreign exchange difference	5,555,000	739,486,345
Unrealised foreign exchange loss		
Total	4,993,620,423	1,958,160,332

28 Selling expenses

	This period	Last period
Raw materials	104,663,518	190,463,885
Labour expenses	5,280,491,668	7,559,660,798
Depreciation expenses	1,074,632,733	310,537,482
Provision/Reversal of provision for product warranty	1,022,691,485	-598,584,403
Expenses of outsourcing services	3,676,255,583	
Other expenses in cash	1,112,881,418	6,328,270,742
Total	12,271,616,405	13,790,348,504

29 Administrative expenses

	This period	Last period
Labour expenses	4,872,949,065	4,260,746,701
Tools and stationery expenses	229,305,688	127,943,294
Depreciation expenses	146,580,182	190,885,345
Provision expenses	93,127,996	-349,104,899
Depreciation expense	2,064,299,954	2,616,155,265
Other expenses in cash	744,530,060	6,192,787,695
Outsourced expense		11,252,899
Total	8,150,792,945	13,039,413,401

30 Other income

	This period	Last period
Income from liquidation of fixed assets, suppliers, tools	2,727,705,836	1,580,935,917
Support and bonuses from suppliers	10,066,741	1,400,862,931
Others	29,358	1,047,979
Total	2,737,801,935	2,982,846,827

31 Other Expenses

	This period	Last period
Others	58,626	244,917,236
Total	58,626	244,917,236

32 Corporate income tax expense

	This period	Last period
Corporate income tax expense calculated on taxable income for the current year	2,770,177,283	2,150,939,282
	2,770,177,283	2,150,939,282

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

From 01 Jul 2025 to 30 Sep 2025

33 Basic earnings per share

Basic earnings per share distributed to common shareholders of the company are calculated as follows:

	This period	Last period
Net profit after tax	12,288,804,483	8,435,131,503
Profit distributed to common shares	12,288,804,483	8,435,131,503
Average number of outstanding common shares in circulation in the period	112,500,171	112,500,171
Basic earnings per share	109.23	74.98

The company has not planned to make any distribution to Bonus and welfare fund, bonus for the Board of Directors from the net profit after tax at the date of preparing interim Consolidated financial statements.

34 OFF STATEMENT OF FINANCIAL POSITION ITEMS

Foreign currencies

		30-Sep-25	01-Jan-25
		100	100
- USD			
Doubtful debts written-off			
Object	Value	Solving Time	Reason
Trade receivables	59,267,731,518	31/03/2022	Unrecoverable
Advances to suppliers	14,944,250,000	31/03/2022	Unrecoverable
Other receivables	16,666,407,839	31/03/2022	Unrecoverable
Trade receivables	240,679,310,430	31/03/2025	Unrecoverable
Advances to suppliers	307,847,523,800	31/03/2025	Unrecoverable
Other receivables	584,571,745,440	31/03/2025	Unrecoverable

35 SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

Outstanding balances up to the reporting date are as follows:

		Relationship	30/09/2025	01/01/2025
			VND	VND
Other short-term receivables				
- Tasco Joint Stock Company	Related Company		34 127 520	32,918,400

Transactions with Related Parties as follow:

	This Period	Last Period
Remuneration of the Board of Directors, the Board of Supervisors, and the Board of Management	1,075,900,000	1,515,728,766

Preparer

Chief Accountant

General Director







Nguyen Thi Lua

Nguyen Ngoc Cuong

Vu Van Toan

Appendix No. 01

13 Tangible Fixed Assets

	Buildings and structures	Machinery	Office Equipments	Trasportation Vehicle	Others	Total
	VND	VND	VND	VND	VND	VND
HISTORICAL COST						
Balance on 01 Jan 2025	4,695,208,182	556,962,997,867	3,433,831,657	7,898,146,408	-	572,990,184,114
Purchasing	-	6,149,545,188	325,010,488	2,142,396,363	-	8,616,952,039
Liquidation, disposal	-	(8,187,399,838)	(325,010,488)	-	-	(8,512,410,326)
Balance on 30 Sep 2025	4,695,208,182	554,925,143,217	3,433,831,657	10,040,542,771	-	573,094,725,827
ACCUMULATED DEPRECIATION						
Balance on 01 Jan 2025	2,851,535,097	462,994,650,665	1,898,234,862	5,298,661,754	-	473,043,082,378
Depreciation	704,281,230	16,329,252,302	276,857,460	900,611,358	-	18,211,002,350
Liquidation, disposal	-	(4,896,758,701)	(19,386,320)	(262,418,182)	-	(5,178,563,203)
Other increase/decrease	-	(2,301,212,828)	-	-	-	(2,301,212,828)
Balance on 30 Sep 2025	3,555,816,327	472,125,931,438	2,155,706,002	5,936,854,930	-	483,774,308,697
CARRYING AMOUNT						
Balance on 01 Jan 2025	1,843,673,085	93,968,347,202	1,535,596,795	2,599,484,654	-	99,947,101,736
Balance on 30 Sep 2025	1,139,391,855	82,799,211,779	1,278,125,655	4,103,687,841	-	89,320,417,130

Appendix No. 02

14 Intangible fixed assets

	Unlimited-term land use rights	Limited-term land use rights	Software	Others	Total
	VND	VND	VND 0	VND	VND
HISTORICAL COST					
Balance on 01/01/2025	-	-	5,313,999,620	-	5,313,999,620
Balance on 30/09/2025	-	-	5,313,999,620	-	5,313,999,620
ACCUMULATED DEPRECIATION					
Balance on 01/01/2025	-	-	3,994,984,795	-	3,994,984,795
Depreciation	-	-	229,290,572	-	229,290,572
Balance on 30/09/2025	-	-	4,224,275,367	-	4,224,275,367
CARRYING AMOUNT					
Balance on 01/01/2025	-	-	1,319,014,825	-	1,319,014,825
Balance on 30/09/2025	-	-	1,089,724,253	-	1,089,724,253

Appendix No. 03

18 Taxes and other payables to State Budget

	Opening balance		Arising during period				Ending Balance	
	Receivables	Payables	Payable amount	Paid amount	Increase due to consolidation	Decrease due to consolidation	Receivables	Payables
	01/01/2025	01/01/2025					30/09/2025	30/09/2025
		VND		VND		VND		VND
- Output VAT	-	2,633,648,855	4,365,605,033	6,513,523,273	-	-	-	485,730,615
- VAT of imported goods	-	-	4,721,477,195	4,721,477,195	-	-	-	-
- Special consumption tax	-	-	-	-	-	-	-	-
- Importing and exporting tax	-	-	388,681,925	388,681,925	-	-	-	-
- Coporate income tax	-	19,136,154,709	8,279,185,471	16,477,021,388	-	-	-	10,938,318,792
- Personal income tax	-	350,385,381	4,878,230,728	4,991,163,933	-	-	-	237,452,176
- Real estate tax, land rent	-	-	-	-	-	-	-	-
- Environmental protection tax and other taxes	4,941,768	3,319,675,156	33,722,285	3,348,397,440	-	-	-	58,233
Total	4,941,768	25,439,864,101	22,666,902,637	36,440,265,154	-	-	-	11,661,559,816

DISCLOSURE OF CONSOLIDATED FINANCIAL STATEMENT (continued)

From 01/07/2025 to 30/09/2025

Appendix No. 04

20 Loans and finance leases

	01/01/2025		During period	30/09/2025
	VND		VND	VND
	Value/Repayment Capability	Increase	Decrease	Value/Repayment Capability
Short-term loans	140,628,685,046	465,211,673,672	327,693,730,694	278,146,628,024
Loans from banks and credit institutions	140,628,685,046	465,211,673,672	327,693,730,694	278,146,628,024
	14,124,403,946	36,423,095,562	36,901,589,987	13,645,909,521
BIDV - My Dinh Branch (1)	64,640,719,208	91,070,563,853	95,980,471,902	59,730,811,159
MB - So giao dich 1 Branch (2)	16,992,576,804	88,701,269,634	64,009,625,145	41,684,221,293
Vietcombank - Ha Thanh Branch (3)	25,449,365,096	111,442,087,472	59,333,627,396	77,557,825,172
Vietinbank - Thang Long Branch (4)	8,734,617,834	-	8,734,617,834	-
ABBank - Hanoi Branch (5)	10,687,002,158	47,902,009,342	51,300,138,508	7,288,872,992
TPBank - Hanoi Branch (6)	-	13,842,820,522	11,433,659,922	2,409,160,600
VPBank - Ngo Quyen Branch (7)	-	75,829,827,287	-	75,829,827,287
SHB -Thang Long Branch (8)	-	35,047,822,238	2,070,000,000	32,977,822,238
Long-term loans and finance leases	-	9,700,000,000	485,000,000	9,215,000,000
BIDV (9)	-	25,347,822,238	1,585,000,000	23,762,822,238
SHB -Thang Long Branch (10)				

DISCLOSURE OF CONSOLIDATED FINANCIAL STATEMENT (continued)

From 01/07/2025 to 30/09/2025

Detailed information related to loans:

(1) Loan under Credit Facility Agreement No. 01/2024/6453135/HDTD dated 11 July 2024 between the Company and Joint Stock Commercial Bank for Investment and Development of Vietnam (My Dinh Branch). The total credit facility limit is VND 35,000,000,000. Purpose: to supplement working capital for the Company's regular production and business activities. The interest rate is specified in each individual loan/drawdown agreement. The loan is secured by a term deposit contract and the Company's fixed assets.

(2) Loan under Credit Facility Agreements No. 233293.24.002.449769.TD dated 23 July 2024 and No. 311578.25.002.449769.TD dated 26 June 2025 between the Company and Military Commercial Joint Stock Bank (Transaction Office 1 Branch). The total facility limit is VND 140,000,000,000, with final maturity on 26 June 2026. Purpose: to supplement working capital for the Company's regular production and business activities. The interest rate is specified in each individual loan/drawdown agreement. The loan is secured by machinery and equipment, goods, and rights to collect receivables owned by Japan Vietnam Medical Investment and Development Joint Stock Company.

(3) Loan under Credit Facility Agreements No. 24/8767425-CTD/017 dated 13 May 2024 and No. 24/8767425-CTD/018 dated 20 May 2025 between the Company and the Joint Stock Commercial Bank for Foreign Trade of Vietnam (Vietcombank) – Ha Thanh Branch. Total facility limit: VND 45,000,000,000. Purpose: supplement working capital for the Company's regular production and business activities. Interest rate specified in each drawdown/loan agreement. Collateral: term deposit contracts and the Company's and third parties' fixed assets and real estate.

(4) Loan under Credit Facility Agreements No. 05/2024-HDCVHM/NHCT236-VIETNHAT dated 15 May 2024 and No. 06/2025-HDCBLHM/NHCT326-VIET NHAT dated 06 June 2025 between the Company and Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) – Thang Long Branch. Total facility limit: VND 120,000,000,000. Purpose: supplement working capital for the Company's regular production and business activities. Interest rate specified in each individual loan/drawdown agreement. Collateral: real estate and fixed assets of the Company and third parties.

(5) Loan under Loan Agreement No. 817/24/TD/SME/011 dated July 16, 2024 between the Company and An Binh Commercial Joint Stock Bank - Hanoi Branch. Total credit limit is 70,000,000,000 VND. The Company fully settled all loans in Q1/2025 and currently has no outstanding debt.

(6) The loan was granted under Credit Contract No. 537/2024/HDTD/DDO dated 11 November 2024 between the Company and Tien Phong Commercial Joint Stock Bank – Hanoi Branch. The total credit limit is VND 120,000,000,000, with a term of 06 months from the disbursement date. The loan interest rate is 6% (6) Loan under Loan Agreement No. 537/2024/HDTD/DDO dated 11 November 2024 between the Company and Tien Phong Commercial Joint Stock Bank (TPBank) – Hanoi Branch. Total credit limit: VND 120,000,000,000. Tenor: 6 months from the disbursement date. Collateral: term deposit contract and receivable rights arising from economic contracts.

(7) The loan under Credit Contract No. 0901/2025 dated January 9, 2025 between the Company and Vietnam Prosperity Joint Stock Commercial Bank – Ngo Quyen Branch. The total credit limit is VND 50,000,000,000, with a term of 6 months from the disbursement date. The collateral for the loan is the receivables arising from economic contracts.

DISCLOSURE OF CONSOLIDATED FINANCIAL STATEMENT (continued)

From 01/07/2025 to 30/09/2025

(8) The loan under Credit Agreement No. 0010/2025/HDHM-PN/SHB.110601 dated July 10, 2025 between the Company and Saigon – Hanoi Commercial Joint Stock Bank, Thang Long Branch. The total credit limit is VND 280,000,000,000. The total loan value is VND 75,000,000,000, with a term of 6 months from the disbursement date. The collateral for the loan is the Company's owner's equity contribution.

(9) The loan under Credit Facility Agreement No. 01/2025/16246050 between the Company and the Bank for Investment and Development of Vietnam (BIDV). The total credit limit is VND 9,700,000,000. The purpose of the loan is to supplement working capital to serve the Company's regular production and business activities. The loan interest rate is specified in each specific debt acknowledgment agreement. The collateral for the loan includes deposit contracts and fixed assets, real estate of the Company and third parties.

(10) The loan under Credit Facility Agreement No. 0014/2025/HHM-PN/SHB.110601 dated June 11, 2024 between the Company and Saigon – Hanoi Commercial Joint Stock Bank. The total credit limit is VND 28,662,377,329. The purpose of the loan is to supplement working capital to serve the Company's regular production and business activities. The loan interest rate is specified in each specific debt acknowledgment agreement. The collateral for the loan includes time deposit contracts and the Company's fixed assets.

DISCLOSURE OF CONSOLIDATED FINANCIAL STATEMENT (continued)

From 01/07/2025 to 30/09/2025

22 Changing in owner's equity

	Paid-in capital of owners	Share premium	Development fund	Treasury stock	Retained Earnings	Non-controlling interest	Total
	VND	VND	VND	VND	VND	VND	VND
<i>For the year ended 30 Sep 2025</i>							
Balance on 01 Jan 2025	1,125,001,710,000	402,288,328,850	19,211,235,252	-	(1,007,069,805,417)	250,159,515	539,681,628,200
Profit of the year	-	-	-	-	39,734,635,155	255,956,400	39,990,591,555
Balance on 30 Sep 2025	1,125,001,710,000	402,288,328,850	19,211,235,252	-	(967,335,170,262)	506,115,915	579,672,219,755

